Cellular Therapies Begin to Make Their Mark in Solid Tumors
OncLive spoke with experts working to develop cellular therapies in solid tumors to gain insights into their current standing and future in the space.
Related Articles
The OncFive: Top Oncology Articles for the Week of 8/10
Vepdegestrant NDA under FDA review in ESR1-mutated breast cancer, Oncomine Dx Target Test gets greenlit as zongertinib companion diagnostic in NSCLC.
Casdatifan Plus Cabozantinib Shows Meaningful Clinical Activity in Pretreated ccRCC
Treatment with casdatifan in combination with cabozantinib produced responses and was safe in patients with pretreated clear cell renal cell carcinoma.
Zidesamtinib Is Set to Overcome the Limitations of Current ROS1 TKIs in in ROS1+ NSCLC
Joshua K. Sabari, MD, discusses the design of the phase 1/2 ARROS-1 study, as well as key efficacy data with zidesamtinib in ROS1 fusionâpositive NSCLC.
Dr DeAngelo on Challenges With Utilizing Pediatric-Inspired Regimens in Adult and AYA ALL
Daniel DeAngelo, MD, PhD, shares the rationale behind a meta analysis of asparaginase regimens vs hyperâCVAD in adult and AYA patients with ALL.
Neoadjuvant Olaparib Plus Carboplatin Reduces Residual Cancer Burden in BRCA1/2-Mutated, HRD+ TNBC
Neoadjuvant olaparib plus carboplatin led to a high RCB 0/1 rate in BRCA1/2-mutated, HRD+ TNBC.
New Treatment Eliminates Bladder Cancer in 82% of Patients
TAR-200 was found to be highly effective in treating select patients with bladder cancer whose tumors were previously unresponsive to therapy.
Novel Lipo-MITâBased Triplet Drives Responses in R/R Myeloma
Bortezomib plus mitoxantrone hydrochloride liposome and dexamethasone produced responses with manageable safety in relapsed/refractory myeloma
Nemvaleukin Alfa Demonstrates Durable Disease Control in Advanced Melanoma and RCC
Nemvaleukin alfa produced a disease control rate of 50% in advanced melanoma and RCC.
Clinical Development Is Discontinued for SGR-2921 in R/R AML and Higher-Risk MDS
The development of SGR-2921 in relapsed/refractory AML and higher-risk MDS was discontinued followed by 2 patient deaths.
Understanding Hematology/Oncology Clinical Trials Is Crucial to Patient Communication
Matthew Hadfield, DO, discusses how hematology/oncology fellows should approach the interpretation of clinical trial data.